<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ophthalmic Inflamm Infect</journal-id><journal-id journal-id-type="iso-abbrev">J Ophthalmic Inflamm Infect</journal-id><journal-title-group><journal-title>Journal of Ophthalmic Inflammation and Infection</journal-title></journal-title-group><issn pub-type="epub">1869-5760</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40000515</article-id><article-id pub-id-type="pmc">PMC11861789</article-id>
<article-id pub-id-type="publisher-id">461</article-id><article-id pub-id-type="doi">10.1186/s12348-025-00461-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Quantitative levels of interferon gamma as a biomarker in the aqueous and serum samples of infectious and noninfectious uveitis patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Shaban</surname><given-names>Sahar Saad Eldeen Mohamed</given-names></name><address><email>Sahar.SaadEldeen@azhar.edu.eg</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Safwat</surname><given-names>Hend Mohammed</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Abdelmohymen</surname><given-names>Abeer Mohammed</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hassan</surname><given-names>Donia Ahmed</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mansour</surname><given-names>Mona Nabeh</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mohammed</surname><given-names>Hanan Said</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Seliem</surname><given-names>Nora</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>El Attar</surname><given-names>Shahinaz</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Amin</surname><given-names>Doaa Refaat</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Khirala</surname><given-names>Seham Kamal Ahmed</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ghamry</surname><given-names>Aya Ahmed</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Anany</surname><given-names>Mona Gamal El Din Al</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mohammed</surname><given-names>Shaymaa Fathy</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05fnp1145</institution-id><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Faculty of Medicine (for Girls), </institution><institution>Al-Azhar University, </institution></institution-wrap>Cairo, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>12</elocation-id><history><date date-type="received"><day>6</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To study the utility of interferon gamma (IFN-&#x003b3;) as a differentiating biomarker by assessing the aqueous humour and serum of patients with infectious and noninfectious uveitis.</p></sec><sec><title>Methods</title><p id="Par2">A total of 40 patients with acute uveitis were divided into 2 groups (18 patients with infectious uveitis and 22 patients with noninfectious uveitis). All the subjects underwent a full ophthalmological examination. Aqueous humour (AqH) and serum samples were collected from uveitis patients. The quantitative levels of IFN-&#x003b3; in aqueous medium and serum were measured by means of an enzyme-linked immunosorbent assay (ELISA).</p></sec><sec><title>Results</title><p id="Par3">The quantitative level of IFN-&#x003b3; in the aqueous humour was significantly greater (87.5&#x02009;&#x000b1;&#x02009;81) (pg/ml) in infectious uveitis patients than in noninfectious uveitis patients (37.3&#x02009;&#x000b1;&#x02009;9.9) (pg/ml) (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.006). However, the serum IFN-&#x003b3; level (pg/ml) did not significantly differ between these groups (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.279). Thus, the IFN-&#x003b3; level in the aqueous humour can be used to discriminate between infectious and noninfectious uveitis with 33.3% sensitivity and 100% specificity.</p></sec><sec><title>Conclusion</title><p id="Par4">Aqueous IFN-&#x003b3; can be used as a biomarker for differentiating between infectious and noninfectious uveitis.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Uveitis</kwd><kwd>Biomarker</kwd><kwd>Infectious</kwd><kwd>Noninfectious</kwd><kwd>Interferon gamma</kwd></kwd-group><funding-group><award-group><funding-source><institution>Al-Azhar University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Uveitis is defined as inflammation of the uveal tissue, which consists of the iris, ciliary body, and choroid. Uveitis frequently involves the impairment of adjacent ocular structures. It has a low incidence, estimated at 17&#x02013;52/100,000 people per year. However, it accounts for approximately 10% of all cases of blindness worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Uveitis can be caused by infectious agents (infectious uveitis) or it can arise in the absence of any detectable infectious agents (noninfectious uveitis), which can be idiopathic or result from immune-mediated processes or systemic disorders [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par6">Identifying the correct treatment approach for uveitis is often a challenge for the ophthalmologist. One of these challenges is that uveitis encompasses a wide variety of pathologies, either systemic or nonsystemic, which may present with a wide range of clinical manifestations, sometimes resulting in a misleading diagnosis and consequently delaying correct treatments [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par7">Although the exact pathophysiological mechanism underlying uveitis is not completely understood, the cytokine and chemokine balance appears to play a critical role in the pathway of this entity [<xref ref-type="bibr" rid="CR4">4</xref>]. Cytokines and chemokines are proteins derived from mononuclear phagocytic cells and T lymphocytes during their growth, differentiation and activation. They regulate all immune and inflammatory responses and are crucial mediators of cytotoxic, humoral, cell-mediated and allergic immunity, and their imbalance could lead to a disturbance in the response of the immune system [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par8">Several studies have reported increased levels of cytokines/chemokines in the plasma, vitreous or AqH of uveitis patients. According to many of these studies, the most abundant cytokine detected in both infectious and noninfectious uveitis is IFN-&#x003b3; [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Similarly, some cytokines have been shown to induce inflammation in experimental animals after intraocular injection [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par9">IFN-&#x003b3; is a dimeric soluble cytokine. It is a crucial cytokine of the CD4 T helper 1 (Th1) subset and is responsible for the delayed hypersensitivity immune response. In vitro T-cell responses can be evaluated by estimating either the number of IFN-&#x003b3;-producing T cells or by measuring IFN-&#x003b3; production via ELISA [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par10">We examined AqH and peripheral blood samples from patients with uveitis for IFN-&#x003b3;. We hypothesized that quantitative level analysis of this cytokine can be used to differentiate between infectious and noninfectious causes of uveitis, especially when the clinical course is challenging.</p></sec><sec id="Sec2"><title>Patients and methods</title><p id="Par11">This single-centre prospective, cross-sectional, nonrandomized study included a total of 40 patients with uveitis divided into 2 groups (Group I, Infectious Type, and Group II, Noninfectious Type) who were older than 18 years. Only patients with acute uveitis (according to the SUN criteria) were enrolled. All the patients had already been diagnosed before the samples were taken to avoid overlap in the diagnoses of the patients. We considered aetiological (infectious versus noninfectious) classification rather than anatomical classification because this study aimed to assess the diagnostic value of interferon in aqueous humour, which is not biased by using anatomical classification.</p><p id="Par12">Patients with uveitis receiving systemic medications before samples were taken were excluded. Patients with any ocular or systemic malignancy were also excluded. None of the patients had a recent history of vaccination, including COVID-19 vaccination. All patients were immunocompetent, and none of them were immunocompromised. All patients were enrolled from the Outpatient Ophthalmology Clinic of our affiliated University Hospital from October 2023 to May 2024. All the participants provided informed written consent before enrolment in the study. The clinical study was approved by Al-Azhar&#x02019;s University Ethics Committee.</p><p id="Par13">All study subjects underwent a complete ophthalmological examination, including best corrected visual acuity (BCVA) measurement using a Snellen chart, slit-lamp biomicroscopy for anterior segment examination, IOP measurement using Goldmann applanation tonometry, and fundus examination.</p><p id="Par14">The diagnosis of herpetic anterior uveitis (AU) and acute retinal necrosis (ARN) in immunocompetent patients was made via the detection of DNA from herpes simplex virus (HSV) or varicella-zoster virus (HZV) in the cellular component of AqH by PCR. Ocular toxoplasmosis was confirmed by increasing serum anti-toxoplasma titres of IgM or IgG in successive serum samples, plus clinical criteria (focal retinitis with severe vitritis) [<xref ref-type="bibr" rid="CR16">16</xref>]. Cytomegalovirus (CMV) AU in immunocompetent patients was determined by detecting IgM antibodies in the blood sample plus clinical criteria (unilateral coin-shaped dusty KPs, cells and high IOP). Infectious neuroretinitis was determined by an increasing Bartonella IgG titre&#x02009;&#x0003e;&#x02009;1:64 with a classic history of cat scratch exposure.</p><p id="Par15">Ocular sarcoidosis was diagnosed according to the criteria established at the International Workshop of Ocular Sarcoidosis (IWOS). Beh&#x000e7;et&#x02019;s disease (BD) was diagnosed according to the preferred criteria for BD published by the International Study Group (ISG). HLA-B27-associated AAU was diagnosed by HLA typing of peripheral blood cells plus clinical criteria.</p><p id="Par16">AqH was sampled at the outpatient clinic under a slit lamp after the surface of the cornea and conjunctiva was sterilized with 5% povidone iodine for 3&#x000a0;min and then washed. Approximately 100 &#x003bc;L of AqH was taken from each patient via limbal paracentesis with the use of a 30-gauge needle. AqH samples were aliquoted and frozen at -20&#x000a0;&#x000b0;C for later analysis of gamma-interferon. Serum samples were taken from uveitis patients. One ml of peripheral venous blood was withdrawn and collected in a serum separator tube, allowed to clot for 30&#x000a0;min at room temperature, and centrifuged for 15&#x000a0;min at 1000 &#x000d7; g. Serum was aliquoted and frozen at -20&#x000a0;&#x000b0;C for later analysis of IFN-&#x003b3;.</p><p id="Par17">Serum and aqueous IFN-&#x003b3; levels were measured by a quantitative double-antibody sandwich ELISA kit supplied by the Bio-Techne R&#x00026;D system (USA, Cat. No. DIF50C; AS 1851 Das; Italy (reader) and 16041412 Bio Tek; USA (washer)). All patients underwent standard baseline investigations for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.</p><p id="Par18">Data were collected, revised, coded and introduced to a PC using the Statistical Package for Social Science (IBM SPSS) version 23. The data are reported as the means&#x02009;&#x000b1;&#x02009;standard deviations (SDs). Statistical comparisons of both groups were conducted using <italic>t</italic> tests, with a <italic>p</italic>&#x02009;value&#x02009;&#x0003c;&#x02009;0.05 considered statistically significant.</p></sec><sec id="Sec3"><title>Results</title><p id="Par19">Among the 40 patients initially recruited, 18 patients (8 males and 10 females) were included in the infectious group, with a mean age of 32.2&#x02009;&#x000b1;&#x02009;11.1 years (range: 19&#x02013;53 years). The noninfectious group included 22 patients (6 males and 16 females), with a mean age of 39.5&#x02009;&#x000b1;&#x02009;12.5 years (range: 22&#x02013;64 years). The groups did not differ in age or sex (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par20">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Epidemiology and clinical data of both studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Diagnosis</th><th align="left" colspan="6">Clinical Data</th><th align="left" colspan="2">IFN- &#x003b3; (pg/ml)</th></tr></thead><tbody><tr><td align="left">
<bold>I- Infectious Uveitis Group</bold>
</td><td align="left">
<bold>Anatomical type</bold>
</td><td align="left">
<bold>AC Cells</bold>
</td><td align="left"><bold>Age</bold> (years)</td><td align="left">
<bold>Gender</bold>
</td><td align="left">
<bold>BCVA</bold>
</td><td align="left"><bold>IOP</bold> (mmHg)</td><td align="left"><p>
<bold>Serum</bold>
</p><p>
<bold>INF- &#x003b3;</bold>
</p></td><td align="left">
<bold>Aqueous INF- &#x003b3;</bold>
</td></tr><tr><td align="left">Herpetic AU and ARN</td><td align="left">AU and PU</td><td align="left">2</td><td align="left">38</td><td align="left">M</td><td align="left">0.01</td><td align="left">26</td><td align="left">&#x0003c;&#x02009;15.6</td><td align="left">129.2</td></tr><tr><td align="left">Herpetic AU and ARN</td><td align="left">AU and PU</td><td align="left">3</td><td align="left">27</td><td align="left">M</td><td align="left">0.01</td><td align="left">24</td><td align="left">19.7</td><td align="left">219.9</td></tr><tr><td align="left">Herpetic AU and ARN</td><td align="left">AU and PU</td><td align="left">3</td><td align="left">28</td><td align="left">M</td><td align="left">0.01</td><td align="left">24</td><td align="left">&#x0003c;&#x02009;15.6</td><td align="left">217.9</td></tr><tr><td align="left">Herpetic AU</td><td align="left">AU</td><td align="left">4</td><td align="left">48</td><td align="left">F</td><td align="left">0.02</td><td align="left">22</td><td align="left">20.7</td><td align="left">240.6</td></tr><tr><td align="left">Herpetic AU</td><td align="left">AU</td><td align="left">4</td><td align="left">53</td><td align="left">F</td><td align="left">0.04</td><td align="left">18</td><td align="left">&#x0003c;&#x02009;15.6</td><td align="left">215.6</td></tr><tr><td align="left">Herpetic AU</td><td align="left">AU</td><td align="left">3</td><td align="left">34</td><td align="left">F</td><td align="left">0.5</td><td align="left">20</td><td align="left">18.9</td><td align="left">130.5</td></tr><tr><td align="left">Herpetic AU</td><td align="left">AU</td><td align="left">4</td><td align="left">20</td><td align="left">M</td><td align="left">0.01</td><td align="left">16</td><td align="left">24.7</td><td align="left">123.3</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">PU</td><td align="left">0</td><td align="left">17</td><td align="left">M</td><td align="left">0.1</td><td align="left">8</td><td align="left">24.5</td><td align="left">33.5</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">PU</td><td align="left">0</td><td align="left">15</td><td align="left">M</td><td align="left">0.02</td><td align="left">10</td><td align="left">25.9</td><td align="left">35</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">20</td><td align="left">M</td><td align="left">0.01</td><td align="left">4</td><td align="left">24.7</td><td align="left">23.3</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">34</td><td align="left">F</td><td align="left">0.2</td><td align="left">18</td><td align="left">25.8</td><td align="left">31</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">29</td><td align="left">M</td><td align="left">0.2</td><td align="left">15</td><td align="left">25.3</td><td align="left">35</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">34</td><td align="left">F</td><td align="left">0.2</td><td align="left">18</td><td align="left">25.8</td><td align="left">31</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">PU</td><td align="left">1</td><td align="left">25</td><td align="left">F</td><td align="left">0.1</td><td align="left">12</td><td align="left">20.8</td><td align="left">38.5</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">52</td><td align="left">F</td><td align="left">0.02</td><td align="left">12</td><td align="left">18.1</td><td align="left">38.8</td></tr><tr><td align="left">Ocular Toxoplasmosis</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">35</td><td align="left">F</td><td align="left">0.01</td><td align="left">12</td><td align="left">18.4</td><td align="left">48.9</td></tr><tr><td align="left">CMV anterior uveitis</td><td align="left">AU</td><td align="left">3</td><td align="left">36</td><td align="left">F</td><td align="left">0.5</td><td align="left">22</td><td align="left">18.7</td><td align="left">94.5</td></tr><tr><td align="left">Infectious Neuroretinitis</td><td align="left">PU</td><td align="left">0</td><td align="left">35</td><td align="left">F</td><td align="left">0.01</td><td align="left">12</td><td align="left">18.4</td><td align="left">48.9</td></tr><tr><td align="left">
<bold>II-Noninfectious Uveitis Group</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">SLE AU</td><td align="left">AU</td><td align="left">3</td><td align="left">31</td><td align="left">F</td><td align="left">1</td><td align="left">22</td><td align="left">33.3</td><td align="left">&#x0003c;&#x02009;15.6</td></tr><tr><td align="left">SLE AU</td><td align="left">AU</td><td align="left">3</td><td align="left">32</td><td align="left">F</td><td align="left">0.5</td><td align="left">16</td><td align="left">31.5</td><td align="left">42.3</td></tr><tr><td align="left">SLE AU</td><td align="left">AU</td><td align="left">4</td><td align="left">28</td><td align="left">F</td><td align="left">0.7</td><td align="left">18</td><td align="left">33.5</td><td align="left">35.3</td></tr><tr><td align="left">Beh&#x000e7;et&#x02019;s disease</td><td align="left">PU</td><td align="left">0</td><td align="left">29</td><td align="left">M</td><td align="left">0.01</td><td align="left">12</td><td align="left">37.7</td><td align="left">26.9</td></tr><tr><td align="left">Beh&#x000e7;et&#x02019;s disease</td><td align="left">Panuveitis</td><td align="left">2</td><td align="left">32</td><td align="left">M</td><td align="left">0.01</td><td align="left">14</td><td align="left">35.6</td><td align="left">38.9</td></tr><tr><td align="left">Beh&#x000e7;et&#x02019;s disease</td><td align="left">PU</td><td align="left">0</td><td align="left">27</td><td align="left">M</td><td align="left">0.01</td><td align="left">12</td><td align="left">32.9</td><td align="left">36.3</td></tr><tr><td align="left">Ocular sarcoidosis</td><td align="left">AU</td><td align="left">3</td><td align="left">55</td><td align="left">F</td><td align="left">0.1</td><td align="left">17</td><td align="left">&#x0003c;&#x02009;15.6</td><td align="left">37.3</td></tr><tr><td align="left">Ocular sarcoidosis</td><td align="left">AU and PU</td><td align="left">2</td><td align="left">55</td><td align="left">F</td><td align="left">0.1</td><td align="left">17</td><td align="left">21.1</td><td align="left">43.3</td></tr><tr><td align="left">Ocular sarcoidosis</td><td align="left">AU</td><td align="left">4</td><td align="left">43</td><td align="left">F</td><td align="left">0.2</td><td align="left">14</td><td align="left">18.7</td><td align="left">46.7</td></tr><tr><td align="left">Ocular sarcoidosis</td><td align="left">AU and PU</td><td align="left">2</td><td align="left">49</td><td align="left">F</td><td align="left">0.1</td><td align="left">15</td><td align="left">18.7</td><td align="left">45.8</td></tr><tr><td align="left">Ocular sarcoidosis</td><td align="left">PU</td><td align="left">0</td><td align="left">51</td><td align="left">F</td><td align="left">0.1</td><td align="left">12</td><td align="left">19.5</td><td align="left">36.7</td></tr><tr><td align="left">Ocular sarcoidosis</td><td align="left">AU</td><td align="left">2</td><td align="left">40</td><td align="left">F</td><td align="left">0.5</td><td align="left">16</td><td align="left">18.2</td><td align="left">51.1</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">2</td><td align="left">28</td><td align="left">M</td><td align="left">0.7</td><td align="left">14</td><td align="left">20.2</td><td align="left">40.8</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">4</td><td align="left">52</td><td align="left">F</td><td align="left">0.2</td><td align="left">14</td><td align="left">21.1</td><td align="left">33.2</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">2</td><td align="left">34</td><td align="left">F</td><td align="left">0.5</td><td align="left">14</td><td align="left">20.5</td><td align="left">50.1</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">2</td><td align="left">29</td><td align="left">M</td><td align="left">0.5</td><td align="left">14</td><td align="left">18.8</td><td align="left">43.7</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">2</td><td align="left">25</td><td align="left">F</td><td align="left">0.7</td><td align="left">14</td><td align="left">20.2</td><td align="left">50.8</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">2</td><td align="left">22</td><td align="left">F</td><td align="left">0.5</td><td align="left">14</td><td align="left">23.5</td><td align="left">45.3</td></tr><tr><td align="left">HLA-B27- associated AAU</td><td align="left">AU</td><td align="left">3</td><td align="left">60</td><td align="left">F</td><td align="left">0.1</td><td align="left">14</td><td align="left">16.6</td><td align="left">24.4</td></tr><tr><td align="left">HLA-B27- associated A AU</td><td align="left">AU</td><td align="left">3</td><td align="left">64</td><td align="left">M</td><td align="left">0.1</td><td align="left">16</td><td align="left">16.6</td><td align="left">26.5</td></tr><tr><td align="left">Fuch&#x02019;s heterochromic AU</td><td align="left">AU</td><td align="left">1</td><td align="left">40</td><td align="left">F</td><td align="left">0.5</td><td align="left">17</td><td align="left">16.5</td><td align="left">24.4</td></tr><tr><td align="left">Fuch&#x02019;s heterochromic AU</td><td align="left">AU</td><td align="left">1</td><td align="left">44</td><td align="left">F</td><td align="left">0.5</td><td align="left">18</td><td align="left">16.5</td><td align="left">25.7</td></tr></tbody></table><table-wrap-foot><p>AU: anterior uveitis, PU: posterior uveitis, AAU: acute anterior uveitis, M: male. F: female, INF- &#x003b3;: Interferon gamma, BCVA: Best Corrected Visual Acuity, AC: Anterior chamber, IOP: Intraocular pressure</p></table-wrap-foot></table-wrap>
</p><p id="Par21">For the infectious group, aqueous humour and serum samples were obtained from patients with herpetic AU and ARN (<italic>n</italic>&#x02009;=&#x02009;3), herpetic AU alone (<italic>n</italic>&#x02009;=&#x02009;4), cytomegalovirus (CMV) AU (<italic>n</italic>&#x02009;=&#x02009;1), ocular toxoplasmosis (<italic>n</italic>&#x02009;=&#x02009;9), and infectious neuroretinitis (<italic>n</italic>&#x02009;=&#x02009;1). HSV was detected by PCR in aqueous humour samples of the 3 patients with AU with ARN and 2 patients with herpetic AU alone, whereas VZV was detected by PCR in the aqueous humour samples of the other 2 patients with herpetic AU alone.</p><p id="Par22">The noninfectious group included patients with ocular sarcoidosis (<italic>n</italic>&#x02009;=&#x02009;6), Beh&#x000e7;et&#x02019;s disease (BD, <italic>n</italic>&#x02009;=&#x02009;3), HLA-B27-associated acute anterior uveitis (AAU, <italic>n</italic>&#x02009;=&#x02009;8), systemic lupus erythrocytosis (SLE, <italic>n</italic>&#x02009;=&#x02009;3) and Fuchs heterochromic iridocyclitis (<italic>n</italic>&#x02009;=&#x02009;2) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par23">A significant decrease in BCVA in the affected eye was detected in the infectious group (mean&#x02009;=&#x02009;0.11&#x02009;&#x000b1;&#x02009;0.16) compared with that in the noninfectious group (mean&#x02009;=&#x02009;0.35&#x02009;&#x000b1;&#x02009;0.29) (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.003). However, IOP (mmHg) did not significantly differ between the studied groups (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.8).</p><p id="Par24">The level of aqueous INF-&#x003b3; (pg/ml) was significantly greater in the infectious group (87.5&#x02009;&#x000b1;&#x02009;81) than in the noninfectious group (37.3&#x02009;&#x000b1;&#x02009;9.9) (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.006). However, the serum INF-&#x003b3; concentration (pg/ml) did not significantly differ between groups (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.279) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par25">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of INF-&#x003b3; (serum and aqueous) concentrations between the studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left">Infectious Group<break/>(<italic>N</italic>&#x02009;=&#x02009;18)</th><th align="left">Noninfectious Group<break/>(<italic>N</italic>&#x02009;=&#x02009;22)</th><th align="left">T</th><th align="left"><italic>P</italic>&#x02009;value</th></tr></thead><tbody><tr><td align="left" rowspan="2">Serum INF- &#x003b3; (pg/ml)</td><td align="left">Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="left">21&#x02009;&#x000b1;&#x02009;3.8</td><td align="left">23&#x02009;&#x000b1;&#x02009;7.2</td><td char="." align="char" rowspan="2">10.9</td><td align="left" rowspan="2">0.279 NS</td></tr><tr><td align="left">Range</td><td align="left">15.6&#x02013;25.9</td><td align="left">15.6&#x02013;37.7</td></tr><tr><td align="left" rowspan="2">Aqueous INF- &#x003b3; (pg/ml)</td><td align="left">Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="left">87.5&#x02009;&#x000b1;&#x02009;81</td><td align="left">37.3&#x02009;&#x000b1;&#x02009;9.9</td><td char="." align="char" rowspan="2">
<bold>2.88</bold>
</td><td align="left" rowspan="2">
<bold>0.006&#x000a0;S</bold>
</td></tr><tr><td align="left">Range</td><td align="left">23.3-240.6</td><td align="left">15.6&#x02013;51.1</td></tr></tbody></table><table-wrap-foot><p>(T: independent sample T test, S: p&#x02009;value&#x02009;&#x0003c;&#x02009;0.05 is considered significant, NS: p&#x02009;value&#x02009;&#x0003e;&#x02009;0.05 is considered nonsignificant)</p></table-wrap-foot></table-wrap>
</p><p id="Par26">An ROC curve revealed that aqueous INF-&#x003b3; can be used to discriminate between the infectious group and noninfectious group at a cut-off level of &#x0003e;&#x02009;51.1, with 33.3% sensitivity, 100% specificity, 100% positive predictive value (PPV) and 64.7% negative predictive value (NPV) (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.354) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par27">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Diagnostic performance of aqueous INF-&#x003b3; in discriminating between the studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cut off</th><th align="left">AUC</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th><th align="left"><italic>p</italic>&#x02009;value</th></tr></thead><tbody><tr><td align="left">Aqueous INF- &#x003b3;</td><td align="left">&#x0003e;&#x02009;51.1</td><td align="left">0.59</td><td align="left">33.3%</td><td align="left">100%</td><td align="left">100%</td><td align="left">64.7%</td><td align="left">0.354</td></tr></tbody></table><table-wrap-foot><p>(PPV: positive predictive value, AUC: area under the curve, NPV: negative predictive value)</p></table-wrap-foot></table-wrap>
</p><p id="Par28">
<fig id="Fig1"><label>Fig. 1</label><caption><p>ROC curve between the infectious group and noninfectious group with respect to aqueous INF-&#x003b3;</p></caption><graphic xlink:href="12348_2025_461_Fig1_HTML" id="d33e1408"/></fig>
</p><p id="Par29">Compared with the other types of infectious uveitis and noninfectious uveitis, the viral uveitis group presented markedly greater aqueous INF-&#x003b3; production (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par30">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Description of aqueous humour INF-&#x003b3; in patients with uveitis in both studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left" colspan="2">Patients with uveitis in both infectious and noninfectious groups (<italic>n</italic>&#x02009;=&#x02009;40)</th></tr></thead><tbody><tr><td align="left" rowspan="4">Aqueous INF- &#x003b3;</td><td align="left" rowspan="2">&#x0003e;&#x02009;100</td><td align="left">Infectious group</td><td char="." align="char">7</td></tr><tr><td align="left">Noninfectious group</td><td char="." align="char">0</td></tr><tr><td align="left" rowspan="2">&#x0003c;&#x02009;100</td><td align="left">Infectious group</td><td char="." align="char">11</td></tr><tr><td align="left">Noninfectious group</td><td char="." align="char">22</td></tr></tbody></table></table-wrap>
</p><p id="Par31">AC cells and aqueous humour INF-&#x003b3; significantly (<italic>P</italic>&#x02009;=&#x02009;0.001) and positively (<italic>r</italic>&#x02009;=&#x02009;0.729) correlated in patients with infectious uveitis (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>) &#x00026; (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). However, AC cells and aqueous humour INF-&#x003b3; did not correlate (<italic>P</italic>&#x02009;=&#x02009;0.832) in patients with noninfectious uveitis (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>). Moreover, serum INF-&#x003b3; did not correlate with AC cells either patients in the infectious group or those in the noninfectious group (Tables&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref>).</p><p id="Par32">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Correlation between AC cells and aqueous humour INF-&#x003b3; in patients with infectious uveitis</p></caption><graphic xlink:href="12348_2025_461_Fig5_HTML" id="d33e1500"/></fig>
</p><p id="Par33">
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Correlation between AC cells and INF-&#x003b3; in patients with infectious uveitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">AC Cells</th></tr><tr><th align="left">
<italic>r</italic>
</th><th align="left"><italic>P</italic>&#x02009;value</th></tr></thead><tbody><tr><td align="left">Serum INF- &#x003b3;</td><td char="." align="char">-0.318</td><td char="." align="char">0.198</td></tr><tr><td align="left">Aqueous INF- &#x003b3;</td><td char="." align="char">0.729</td><td char="." align="char">0.001</td></tr></tbody></table><table-wrap-foot><p>(r): Pearson correlation coefficient. A P value&#x02009;&#x0003c;&#x02009;0.05 was considered significant</p></table-wrap-foot></table-wrap>
</p><p id="Par34">
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Correlation between AC cells and INF-&#x003b3; in patients with noninfectious uveitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">AC Cells</th></tr><tr><th align="left">
<italic>r</italic>
</th><th align="left"><italic>P</italic>&#x02009;value</th></tr></thead><tbody><tr><td align="left">Serum INF- &#x003b3;</td><td char="." align="char">0.191</td><td char="." align="char">0.395</td></tr><tr><td align="left">Aqueous INF- &#x003b3;</td><td char="." align="char">-0.048</td><td char="." align="char">0.832</td></tr></tbody></table><table-wrap-foot><p>(r): Pearson correlation coefficient. A P value&#x02009;&#x0003e;&#x02009;0.05 was considered nonsignificant</p></table-wrap-foot></table-wrap>
</p><p id="Par35">The serum INF-&#x003b3; concentration significantly and negatively correlated with age in both the infectious and noninfectious groups (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.01 and <italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.004, respectively) (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). Additionally, the serum INF-&#x003b3; concentration and aqueous humour INF-&#x003b3; concentration significantly and negatively correlated in the infectious group (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.009) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par36">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Correlations between the serum INF-&#x003b3; concentration and age in the infectious group</p></caption><graphic xlink:href="12348_2025_461_Fig2_HTML" id="d33e1623"/></fig>
</p><p id="Par37">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Correlations between the serum INF-&#x003b3; concentration and age in the noninfectious group</p></caption><graphic xlink:href="12348_2025_461_Fig3_HTML" id="d33e1633"/></fig>
</p><p id="Par38">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Correlations between the serum &#x003b3;-INF concentration and aqueous INF-&#x003b3; concentration in the infection group</p></caption><graphic xlink:href="12348_2025_461_Fig4_HTML" id="d33e1643"/></fig>
</p></sec><sec id="Sec5"><title>Discussion</title><p id="Par39">Differentiating between infectious and noninfectious uveitis is highly important because the disease course, outcome, and therapeutic approach are entirely different in each situation. Ocular infections can be significantly worsened in the presence of local or systemic steroids or immunosuppression agents, as these favour increased replication of the infective agent. In addition, these patients may present with atypical manifestations of the disease. Some infectious organisms can also be latent in the eye and reactivated after the introduction of local steroids. For these reasons, infectious uveitis needs to be carefully excluded prior to the administration of steroid or immunosuppressive therapies [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par40">Recognition and appropriate work-up of an infectious cause of uveitis and early initiation of targeted anti-infective treatment are important to preserve vision. PCR analysis serves as an important diagnostic tool to establish or exclude the infectious aetiology of uveitis. However, the financial and time-consuming burden of PCR profile analysis for uveitis patients, especially in developing countries, delays the diagnosis and, hence, the early initiation of proper treatment [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par41">Thus, an easy, rapid access and screening test for differentiating infectious uveitis from noninfectious uveitis is urgently needed. The focus of many recent studies has been the development of new biomarkers to aid in accurate diagnosis and significantly shift the current management of ocular inflammation [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par42">Building on previous studies showing that (IFN-&#x003b3;) is the most abundant cytokine detected in uveitis [<xref ref-type="bibr" rid="CR14">14</xref>], our study involved the estimation of the quantitative IFN-&#x003b3; level in AqH and the sera of patients with infectious and noninfectious uveitis. This level was measured using ELISA. Samples were collected only from patients who had a strictly diagnosed type of uveitis with acute inflammation in the anterior chamber. In addition, none of the patients had been treated with systemic or topical steroids before the samples were taken. Therefore, all patients in each clinical group can be regarded as being in similar condition.</p><p id="Par43">Our results revealed a statistically significant decrease in BCVA in the affected eye in the infectious group (mean&#x02009;=&#x02009;0.11&#x02009;&#x000b1;&#x02009;0.16) compared with that in the noninfectious group (mean&#x02009;=&#x02009;0.35&#x02009;&#x000b1;&#x02009;0.29) (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.003). We believe that this finding arose because most cases of infectious uveitis in this study were associated with posterior segment involvement or anterior involvement complicated with high IOP that blurred vision. Therefore, the BCVA during acute attack in infectious uveitis was significantly lower than that in the noninfectious type because of the specific infectious uveitis criteria in those patients rather than the nature of the infectious uveitis in general.</p><p id="Par44">In our study, the INF-&#x003b3; level in the aqueous humour was significantly greater in the infectious group, with a mean value of 96.4&#x02009;&#x000b1;&#x02009;78.4 (pg/ml) (almost twice as high) than in the noninfectious group (38.3&#x02009;&#x000b1;&#x02009;8.9) (pg/ml) (<italic>p</italic>&#x02009;value&#x02009;=&#x02009;0.006). However, the serum INF-&#x003b3; level did not significantly differ between these groups. The INF-&#x003b3; level in the aqueous humour of patients with viral uveitis was markedly increased, with a maximum value (240.6 pg/ml), compared with that in patients with other types of infectious uveitis and noninfectious uveitis.</p><p id="Par45">These results agree with those of Takase et al. [<xref ref-type="bibr" rid="CR14">14</xref>], who aimed to determine the cytokine expression profile at the protein level in the AqH and serum of patients with infectious and noninfectious uveitis. The level of IFN-&#x003b3; in the aqueous humour notably differed between the two groups. The mean IFN-&#x003b3; level in the aqueous humour of patients with infectious uveitis was 324.5 pg/mL, which was almost 3 times greater than that in patients with noninfectious uveitis (mean, 115.6 pg/mL; <italic>P</italic>&#x02009;=&#x02009;0.00289). Additionally, the level of INF-&#x003b3; in the aqueous humour of ARN patients was markedly increased, with a maximum of 571.4 pg/ml, compared with that in patients with other types of infectious uveitis and noninfectious uveitis. However, in this study, the infectious uveitis cases involved were all viral uveitis cases. This fact explains the greater mean IFN-&#x003b3; level in the aqueous humour of patients in the infectious uveitis group in this study. IFN-&#x003b3; was detected in the sera of half of the patients with infectious uveitis, although the concentrations were close to the detection limit.</p><p id="Par46">On the other hand, Lacomba et al. [<xref ref-type="bibr" rid="CR4">4</xref>] assessed the cytokine profile in the AqH and peripheral blood from patients with uveitis and controls. The IFN-&#x003b3; and IL-2 levels in the aqueous humour and serum were greater in samples from patients with uveitis than in those from controls, but the IFN-&#x003b3; levels in the peripheral blood (39.26&#x02009;&#x000b1;&#x02009;34.11 pg/ml) were greater than those in the aqueous humour (13.86&#x02009;&#x000b1;&#x02009;1.68 pg/ml) among these patients. This difference may be due to the variance in the cause, severity, duration and pattern of uveitis in their study compared with the control. In addition, most uveitis cases in that study were due to noninfectious causes.</p><p id="Par47">Based on cytokine/chemokine profile analysis, many studies have reported increased levels of IFN-&#x003b3; in either the plasma or AqH of uveitis patients compared with controls [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. To our knowledge, this study is the first to evaluate aqueous and serum levels of IFN-&#x003b3; alone in patients with infectious and noninfectious uveitis.</p><p id="Par48">Because the IFN-&#x003b3; level in the aqueous humour is specific rather than sensitive, aqueous IFN-&#x003b3; measurement might be proposed in parallel with the gold standard PCR for differentiating infectious from noninfectious uveitis. A high aqueous IFN-&#x003b3; level should be considered as an additional indicator for infectious uveitis, especially in the case of negative PCR results.</p></sec><sec id="Sec6"><title>Conclusion</title><p id="Par49">We found a significant increase in aqueous humour IFN-&#x003b3; levels in patients with infectious uveitis. Aqueous humour INF-&#x003b3; can be used to discriminate between these two groups with 33.3% sensitivity and 100% specificity. Understanding the role of IFN-&#x003b3; in ocular inflammation may provide new clues for the management of uveitis. Measurements of IFN-&#x003b3; levels in the AqH may also play a role in predicting relapses and monitoring disease activity in patients with uveitis.</p><p id="Par50">The main limitation of this study is the small sample size, which is not sufficient to determine the all infectious and noninfectious causes of uveitis. Also, we depended on the aqueous IFN-&#x003b3; levels in all anatomical types of uveitis and did not consider the vitreous IFN-&#x003b3; levels in PU and panuveitis cases. Further studies involving IFN-&#x003b3; analysis in conjunction with clinical and therapeutic data are needed. In addition, more studies of IFN-&#x003b3; analysis for each disease individually in infectious and noninfectious causes would add more insights into the role of this cytokine in uveitis management.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>(A) E. wrote the main manuscript text. (B) and F. did the clinical work. (C) and D did the laboratory work. I. J. prepared Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, 2, 3 and 4. K. L. and M. did the tables and statistical work. G. and H. do PCR in laboratory work. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). No funding or grant support.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar10"><title>Ethics approval and consent to participate</title><p id="Par51">The study was performed in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Al-Azhar University (Approval no.2023092073). All the participants provided informed written consent before enrolment in the study.</p></notes><notes id="FPar11"><title>Consent for publication</title><p id="Par52">Written consent was obtained from all participants after they were informed about the nature of the study, including their consent for participation and publication.</p></notes><notes id="FPar8" notes-type="COI-statement"><title>Competing interests</title><p id="Par53">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>AAU</term><def><p id="Par54">Acute anterior uveitis</p></def></def-item><def-item><term>AC</term><def><p id="Par55">Anterior chamber</p></def></def-item><def-item><term>AqH</term><def><p id="Par56">Aqueous humour</p></def></def-item><def-item><term>ARN</term><def><p id="Par57">Acute retinal necrosis</p></def></def-item><def-item><term>AU</term><def><p id="Par58">Anterior uveitis</p></def></def-item><def-item><term>BCVA</term><def><p id="Par59">Best corrected visual acuity</p></def></def-item><def-item><term>BD</term><def><p id="Par60">Beh&#x000e7;et&#x02019;s disease</p></def></def-item><def-item><term>CMV</term><def><p id="Par61">Cytomegalovirus</p></def></def-item><def-item><term>CRP</term><def><p id="Par62">C-reactive protein</p></def></def-item><def-item><term>ELISA</term><def><p id="Par63">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>ESR</term><def><p id="Par64">Erythrocyte sedimentation rate</p></def></def-item><def-item><term>HSV</term><def><p id="Par65">Herpes simplex virus</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par66">Interferon Gamma</p></def></def-item><def-item><term>IOP</term><def><p id="Par67">Intraocular pressure</p></def></def-item><def-item><term>ISG</term><def><p id="Par68">International study group</p></def></def-item><def-item><term>IWOS</term><def><p id="Par69">International Workshop of ocular sarcoidosis</p></def></def-item><def-item><term>PCR</term><def><p id="Par70">Polymerase chain reaction</p></def></def-item><def-item><term>Th1</term><def><p id="Par71">T helper1</p></def></def-item><def-item><term>VZV</term><def><p id="Par72">Varicella zoster virus</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Jabs DA (2008) Epidemiology of uveitis. Ophthal Epidemiol. 15:283&#x02013;284. 10.1080/09286580802478724</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego-Pinazo</surname><given-names>R</given-names></name><name><surname>Dolz-Marco</surname><given-names>R</given-names></name><name><surname>Mart&#x000ed;nez-Castillo</surname><given-names>S</given-names></name><name><surname>Ar&#x000e9;valo</surname><given-names>JF</given-names></name><name><surname>D&#x000ed;az-Llopis</surname><given-names>M</given-names></name></person-group><article-title>Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis</article-title><source>Inflamm Allergy Drug Targets</source><year>2013</year><volume>12</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.2174/1871528111312010006</pub-id><pub-id pub-id-type="pmid">23441991</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gallego-Pinazo R, Dolz-Marco R, Mart&#x000ed;nez-Castillo S, Ar&#x000e9;valo JF, D&#x000ed;az-Llopis M (2013) Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets 12:38&#x02013;45. 10.2174/1871528111312010006<pub-id pub-id-type="pmid">23441991</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Gritz</surname><given-names>DC</given-names></name><name><surname>Schwaber</surname><given-names>EJ</given-names></name><name><surname>Wong</surname><given-names>IG</given-names></name></person-group><article-title>Complications of Uveitis: the Northern California epidemiology of Uveitis Study</article-title><source>Ocul Immunol Inflamm</source><year>2018</year><volume>26</volume><fpage>584</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1080/09273948.2016.1247174</pub-id><pub-id pub-id-type="pmid">28112975</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gritz DC, Schwaber EJ, Wong IG (2018) Complications of uveitis: the Northern California epidemiology of uveitis study. Ocul Immunol Inflamm 26:584&#x02013;594. 10.1080/09273948.2016.1247174<pub-id pub-id-type="pmid">28112975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Lacomba</surname><given-names>MS</given-names></name><name><surname>Martin</surname><given-names>CM</given-names></name><name><surname>Chamond</surname><given-names>RR</given-names></name><name><surname>Galera</surname><given-names>JMG</given-names></name><name><surname>Omar</surname><given-names>M</given-names></name><name><surname>Estevez</surname><given-names>EC</given-names></name></person-group><article-title>Aqueous and serum Interferon &#x003b3;, interleukin (IL) 2, IL-4, and IL-10 in patients with Uveitis</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><issue>6</issue><fpage>768</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1001/archopht.118.6.768</pub-id><pub-id pub-id-type="pmid">10865312</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lacomba MS, Martin CM, Chamond RR, Galera JMG, Omar M, Estevez EC (2000) Aqueous and serum Interferon &#x003b3;, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol 118(6):768&#x02013;772<pub-id pub-id-type="pmid">10865312</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Borish</surname><given-names>LC</given-names></name><name><surname>Steinke</surname><given-names>JW</given-names></name></person-group><article-title>2. Cytokines and chemokines</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><fpage>S460</fpage><lpage>S475</lpage><pub-id pub-id-type="doi">10.1067/mai.2003.108</pub-id><pub-id pub-id-type="pmid">12592293</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Borish LC, Steinke JW (2003) 2. Cytokines and chemokines. J Allergy Clin Immunol 111:S460&#x02013;S475<pub-id pub-id-type="pmid">12592293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Onrubia</surname><given-names>L</given-names></name><name><surname>Mateos Olivares</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-V&#x000e1;zquez</surname><given-names>C</given-names></name><name><surname>Enr&#x000ed;quez-de-Salamanca</surname><given-names>A</given-names></name><name><surname>Cocho</surname><given-names>L</given-names></name><name><surname>Herreras Cantalapiedra</surname><given-names>JM</given-names></name></person-group><article-title>Tear and plasma levels of cytokines in patients with Uveitis: search for active disease biomarkers</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><fpage>7034</fpage><pub-id pub-id-type="doi">10.3390/jcm11237034</pub-id><pub-id pub-id-type="pmid">36498608</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Garc&#x000ed;a-Onrubia L, Mateos Olivares M, Garc&#x000ed;a-V&#x000e1;zquez C, Enr&#x000ed;quez-de-Salamanca A, Cocho L, Herreras Cantalapiedra JM (2022) Tear and plasma levels of cytokines in patients with uveitis: search for active disease biomarkers. J Clin Med 11:7034<pub-id pub-id-type="pmid">36498608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Curnow</surname><given-names>SJ</given-names></name><name><surname>Murray</surname><given-names>PI</given-names></name></person-group><article-title>Inflammatory mediators of uveitis: cytokines and chemokines</article-title><source>Curr Opin Ophthalmol</source><year>2006</year><volume>17</volume><fpage>532</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1097/ICU.0b013e32801094b5</pub-id><pub-id pub-id-type="pmid">17065921</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Curnow SJ, Murray PI (2006) Inflammatory mediators of uveitis: cytokines and chemokines. Curr Opin Ophthalmol 17:532&#x02013;537<pub-id pub-id-type="pmid">17065921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>KGJ</given-names></name><name><surname>Galatowicz</surname><given-names>G</given-names></name><name><surname>Calder</surname><given-names>VL</given-names></name><name><surname>Lightman</surname><given-names>SL</given-names></name></person-group><article-title>Cytokines and chemokines in uveitis&#x02014;Is there a correlation with clinical phenotype? Clin</article-title><source>Med Res</source><year>2006</year><volume>4</volume><fpage>294</fpage><lpage>309</lpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ooi KGJ, Galatowicz G, Calder VL, Lightman SL (2006) Cytokines and chemokines in uveitis&#x02014;Is there a correlation with clinical phenotype? Clin. Med Res 4:294&#x02013;309</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Lahmar</surname><given-names>I</given-names></name><name><surname>Abou-Bacar</surname><given-names>A</given-names></name><name><surname>Abdelrahman</surname><given-names>T</given-names></name><name><surname>Guinard</surname><given-names>M</given-names></name><name><surname>Babba</surname><given-names>H</given-names></name><name><surname>Ben Yahia</surname><given-names>S</given-names></name><name><surname>Kairallah</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cytokine profiles in Toxoplasmic and viral Uveitis</article-title><source>J Infect Dis</source><year>2009</year><volume>199</volume><fpage>1239</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1086/597478</pub-id><pub-id pub-id-type="pmid">19302012</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lahmar I, Abou-Bacar A, Abdelrahman T, Guinard M, Babba H, Ben Yahia S, Kairallah M et al (2009) Cytokine profiles in toxoplasmic and viral uveitis. J Infect Dis 199:1239&#x02013;1249<pub-id pub-id-type="pmid">19302012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Abu El-Asrar</surname><given-names>AM</given-names></name><name><surname>Al-Obeidan</surname><given-names>SS</given-names></name><name><surname>Kangave</surname><given-names>D</given-names></name><name><surname>Geboes</surname><given-names>K</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><etal/></person-group><article-title>CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis</article-title><source>Immunobiology</source><year>2011</year><volume>216</volume><fpage>1004</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2011.03.007</pub-id><pub-id pub-id-type="pmid">21531038</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Abu El-Asrar AM, Al-Obeidan SS, Kangave D, Geboes K, Opdenakker G, Van Damme J et al (2011) CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology 216:1004&#x02013;1009<pub-id pub-id-type="pmid">21531038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>JJW</given-names></name><name><surname>Mutis</surname><given-names>T</given-names></name><name><surname>De Jager</surname><given-names>W</given-names></name><name><surname>De Groot-Mijnes</surname><given-names>JDF</given-names></name><name><surname>Rothova</surname><given-names>A</given-names></name></person-group><article-title>Intraocular interleukin-17 and proinflammatory cytokines in HLA-A-29-associated birdshot chorioretinopathy</article-title><source>Am J Ophthalmol</source><year>2011</year><volume>152</volume><fpage>177</fpage><lpage>182e1</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2011.01.031</pub-id><pub-id pub-id-type="pmid">21570674</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kuiper JJW, Mutis T, De Jager W, De Groot-Mijnes JDF, Rothova A (2011) Intraocular interleukin-17 and proinflammatory cytokines in HLA-A-29-associated birdshot chorioretinopathy. Am J Ophthalmol 152:177&#x02013;182e1<pub-id pub-id-type="pmid">21570674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Abu El-Asrar</surname><given-names>AM</given-names></name><name><surname>Struyf</surname><given-names>S</given-names></name><name><surname>Kangave</surname><given-names>D</given-names></name><name><surname>Al-Obeidan</surname><given-names>SA</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name><name><surname>Geboes</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis</article-title><source>Cytokine</source><year>2012</year><volume>59</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2012.04.030</pub-id><pub-id pub-id-type="pmid">22583692</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Abu El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SA, Opdenakker G, Geboes K et al (2012) Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis. Cytokine 59:377&#x02013;381<pub-id pub-id-type="pmid">22583692</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>M</given-names></name><name><surname>Cheung</surname><given-names>G</given-names></name><name><surname>Vania</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chee</surname><given-names>SP</given-names></name></person-group><article-title>Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis</article-title><source>Mol Vis</source><year>2012</year><volume>18</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">22509092</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ang M, Cheung G, Vania M, Chen J, Yang H, Li J, Chee SP (2012) Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis. Mol Vis 18:565&#x02013;573<pub-id pub-id-type="pmid">22509092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Takase</surname><given-names>H</given-names></name><name><surname>Futagami</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Kamoi</surname><given-names>K</given-names></name><name><surname>Sugita</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Mochizuki</surname><given-names>M</given-names></name></person-group><article-title>Cytokine Profile in Aqueous humor and sera of patients with infectious or noninfectious Uveitis</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><issue>4</issue><fpage>1557</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1167/iovs.05-0836</pub-id><pub-id pub-id-type="pmid">16565392</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Takase H, Futagami Y, Yoshida T, Kamoi K, Sugita S, Imai Y, Mochizuki M (2006) Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci 47(4):1557&#x02013;1561<pub-id pub-id-type="pmid">16565392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Albini</surname><given-names>TA</given-names></name><name><surname>Karakousis</surname><given-names>PC</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Interferon-gamma release assays in the diagnosis of tuberculous uveitis</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>146</volume><issue>4</issue><fpage>486</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2008.06.021</pub-id><pub-id pub-id-type="pmid">18804561</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Albini TA, Karakousis PC, Rao NA (2008) Interferon-gamma release assays in the diagnosis of tuberculous uveitis. Am J Ophthalmol 146(4):486&#x02013;488<pub-id pub-id-type="pmid">18804561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalogeropoulos</surname><given-names>D</given-names></name><name><surname>Sakkas</surname><given-names>H</given-names></name><name><surname>Mohammed</surname><given-names>B</given-names></name><name><surname>Vartholomatos</surname><given-names>G</given-names></name><name><surname>Malamos</surname><given-names>K</given-names></name><name><surname>Sreekantam</surname><given-names>S</given-names></name><name><surname>Kanavaros</surname><given-names>P</given-names></name><name><surname>Kalogeropoulos</surname><given-names>C</given-names></name></person-group><article-title>Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches</article-title><source>Int Ophthalmol</source><year>2022</year><volume>42</volume><issue>1</issue><fpage>295</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1007/s10792-021-01994-9</pub-id><pub-id pub-id-type="pmid">34370174</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kalogeropoulos D, Sakkas H, Mohammed B, Vartholomatos G, Malamos K, Sreekantam S, Kanavaros P, Kalogeropoulos C (2022) Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol 42(1):295&#x02013;321<pub-id pub-id-type="pmid">34370174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>APC</given-names></name><name><surname>Sims</surname><given-names>JL</given-names></name><name><surname>Niederer</surname><given-names>RL</given-names></name></person-group><article-title>Infectious uveitis after local steroid and/or methotrexate injections at a Tertiary Referral Center in New Zealand: a Case Series</article-title><source>Ocul Immunol Inflamm</source><year>2021</year><volume>30</volume><issue>5</issue><fpage>1176</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1080/09273948.2020.1860230</pub-id><pub-id pub-id-type="pmid">33792480</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ong APC, Sims JL, Niederer RL (2021) Infectious uveitis after local steroid and/or methotrexate injections at a Tertiary Referral Center in New Zealand: a case series. Ocul Immunol Inflamm 30(5):1176&#x02013;1180. 10.1080/09273948.2020.1860230<pub-id pub-id-type="pmid">33792480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kharel</surname><given-names>R</given-names></name><name><surname>Janani</surname><given-names>MK</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Biswas</surname><given-names>J</given-names></name></person-group><article-title>Outcome of polymerase chain reaction (PCR) analysis in 100 suspected cases of infectious uveitis</article-title><source>J Ophthalmic Inflamm Infect</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s12348-017-0144-1</pub-id><pub-id pub-id-type="pmid">29322275</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kharel R, Janani MK, Madhavan HN, Biswas J (2018) Outcome of polymerase chain reaction (PCR) analysis in 100 suspected cases of infectious uveitis. J Ophthalmic Inflamm Infect 8(1):2<pub-id pub-id-type="pmid">29322275</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>